2020 Revenues ($USD) : $3,115,402,823
2020 Revenues (foreign currencies) : ₹230,985,000,000
2020 R&D spend : $129,209,9445
2020 Number of Employees : 20,000
Fiscal Year End : 3/31/2020
Key People : P.V.Ramprasad Reddy and Mr. K.Nityananda Reddy

Starting in the late 1980s with a single unit manufacturing semi-synthetic penicillin (SSP) in Pondicherry, the Indian company now touts itself as the market leader for SSPs. It has a multi-product portfolio with manufacturing facilities in several countries. On top of antibiotics, it provides therapies in segments including neurosciences, cardiovascular, anti-retroviral, anti-diabetics, and gastroenterology. It boasts one of the largest R&D centers in India and two research centers in the U.S. Aurobindo Pharma is also active in the high-margin specialty generic formulations segment. –CN